Our top pick for
Building a portfolio
Cerus Corporation is a biotechnology business based in the US. Cerus Corporation shares (CERS) are listed on the NASDAQ and all prices are listed in US Dollars. Cerus Corporation employs 254 staff and has a trailing 12-month revenue of around USD$84.6 million.
|Latest market close||USD$7.46|
|52-week range||USD$2.71 - USD$8.87|
|50-day moving average||USD$6.8161|
|200-day moving average||USD$6.5596|
|Wall St. target price||USD$9.3|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.492|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-14)||-1.19%|
|1 month (2020-12-22)||-12.85%|
|3 months (2020-10-21)||19.74%|
|6 months (2020-07-21)||10.19%|
|1 year (2020-01-21)||66.52%|
|2 years (2019-01-18)||31.34%|
|3 years (2018-01-19)||81.07%|
|5 years (2016-01-21)||32.27%|
|Revenue TTM||USD$84.6 million|
|Gross profit TTM||USD$41.2 million|
|Return on assets TTM||-19.98%|
|Return on equity TTM||-73.39%|
|Market capitalisation||USD$1.3 billion|
TTM: trailing 12 months
There are currently 10.5 million Cerus Corporation shares held short by investors – that's known as Cerus Corporation's "short interest". This figure is 2.8% up from 10.2 million last month.
There are a few different ways that this level of interest in shorting Cerus Corporation shares can be evaluated.
Cerus Corporation's "short interest ratio" (SIR) is the quantity of Cerus Corporation shares currently shorted divided by the average quantity of Cerus Corporation shares traded daily (recently around 2.1 million). Cerus Corporation's SIR currently stands at 5.02. In other words for every 100,000 Cerus Corporation shares traded daily on the market, roughly 5020 shares are currently held short.
However Cerus Corporation's short interest can also be evaluated against the total number of Cerus Corporation shares, or, against the total number of tradable Cerus Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Cerus Corporation's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Cerus Corporation shares in existence, roughly 60 shares are currently held short) or 0.0642% of the tradable shares (for every 100,000 tradable Cerus Corporation shares, roughly 64 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Cerus Corporation.
Find out more about how you can short Cerus Corporation stock.
We're not expecting Cerus Corporation to pay a dividend over the next 12 months.
Over the last 12 months, Cerus Corporation's shares have ranged in value from as little as $2.71 up to $8.87. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cerus Corporation's is 1.3486. This would suggest that Cerus Corporation's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma that is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; and INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company has a collaboration with the National Trauma Institute to supply Intercept plasma for use in the plasma resuscitation without lung injury (PROpOLIs) clinical study. Cerus Corporation was founded in 1991 and is headquartered in Concord, California.
Steps to owning and managing SSNC, with 24-hour and historical pricing before you buy.
Steps to owning and managing SMBC, with 24-hour and historical pricing before you buy.
Steps to owning and managing SMED, with 24-hour and historical pricing before you buy.
Steps to owning and managing SJW, with 24-hour and historical pricing before you buy.
Steps to owning and managing SFBS, with 24-hour and historical pricing before you buy.
Steps to owning and managing LEDS, with 24-hour and historical pricing before you buy.
Steps to owning and managing SC, with 24-hour and historical pricing before you buy.
Steps to owning and managing RTW, with 24-hour and historical pricing before you buy.
Steps to owning and managing RIVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing RVSB, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.